Skip to main content
Targeted Oncology
Genetic Alterations
Company
Management Team
Board of Directors
Scientific Advisory Board
Business Development
Careers
Contact
Pipeline
Sitravatinib (MGCD516)
KRAS G12C Inhibitor (MRTX849)
Patients
Investors
Contact
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2019
2018
2017
2016
2015
2014
2013
12/20/2018
Mirati Therapeutics Added To NASDAQ Biotechnology Index
12/10/2018
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
11/29/2018
Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
11/20/2018
Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
11/09/2018
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
11/09/2018
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
11/08/2018
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
11/07/2018
Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
11/06/2018
Mirati Therapeutics Reports Third Quarter Financial Results
11/05/2018
Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
10/30/2018
Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
10/22/2018
Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
10/21/2018
Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
10/15/2018
Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
8/29/2018
Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
8/16/2018
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
8/01/2018
Mirati Therapeutics Reports Second Quarter Financial Results
7/24/2018
Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
6/25/2018
Mirati Therapeutics Added to Russell 2000® Index
6/11/2018
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/07/2018
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
6/06/2018
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
5/31/2018
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
5/30/2018
Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
5/07/2018
Mirati Therapeutics Reports First Quarter Financial Results
4/24/2018
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
3/08/2018
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
3/07/2018
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
2/08/2018
Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
1/08/2018
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region